Table 2.
Treatment characteristics of study population
| Variable | Total patients (n = 93) | Low dose ATG (n = 62) | Standard dose ATG (n = 31) | P value |
|---|---|---|---|---|
| Diagnosis to ATG interval (months, range) | 2 (1,5) | 2 (1,5) | 3 (1,6) | 0.957 |
| Timing of hATG | ||||
| As first-line, n(%) | 58 (62.4) | 37 (59.7) | 21 (67.7) | 0.449 |
| As second-line, n(%) | 35 (37.6) | 25 (40.3) | 10 (32.3) | |
| Eltromobpag with ATG | ||||
| Yes, n(%) | 17 (18.3) | 12 (19.4) | 5 (16.1) | 0.704 |
| No, n(%) | 76 (81.7) | 50 (80.6) | 26 (83.9) | |
| Formulation of ATG | ||||
| ATGAM | 51 (54.8) | 39 (62.9) | 12 (38.7) | 0.027 |
| Thymogam | 42 (45.2) | 23 (37.1) | 19 (61.3) | |
| Duration of IST after ATG (months), median (range) | 25 (12,47) | 25.5 (14.75,51.25) | 25 (9,34) | 0.072 |